

# The impact of the COVID-19 pandemic on the provision, practice, and outcomes of vascular surgery (COVER study)

<b>Submission date</b> 12/04/2020	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 14/04/2020	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 10/03/2022	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

The COVER study is an international study aiming to assess how the COVID-19 coronavirus pandemic has changed the medical care of patients who have artery and vein problems. It consists of three separate projects or "Tiers". The 1st Tier is an internet based survey where doctors and healthcare professionals are asked some questions (every week) about how the care of these patients has changed. The 2nd Tier is a study where each hospital inputs the nature of the surgeries performed every week on an online database. The 3rd Tier is similar to the 2nd Tier; it will collect information on what happens to patients having artery or vein surgery during the pandemic. Finally, we will collect information regarding what happened to these patients for a year.

This study will help healthcare professionals understand how the COVID-19 pandemic has changed the care of patients with artery and vein problems. This is an important question, as patients with such health problems typically have many other health issues and/or are elderly. This makes them it more likely for them to develop COVID-19 related problems and life threatening complications.

### Who can participate?

Any patient with a vascular condition.

### What does the study involve?

Health professionals at participating centres will complete an online survey regarding vascular surgery that has been carried out.

### What are the possible benefits and risks of participating?

None.

### Where is the study run from?

University Hospital Coventry and Warwickshire (UK)

When is the study starting and how long is it expected to run for?  
April 2020 to April 2022

Who is funding the study?  
National Institute for Health Research (NIHR) (UK)

Who is the main contact?  
1. Ruth Benson (public), vern.arterial.disease@gmail.com  
2. Prof Christopher Imray (scientific), vern.arterial.disease@gmail.com  
3. Sandip Nandhra (public), vern.arterial.disease@gmail.com  
4. Prof Matt Bown (scientific), mjb42@le.ac.uk  
5. Ms Ann Elsworth (public), ame29@le.ac.uk

## Contact information

### Type(s)

Public

### Contact name

Miss Ruth Benson

### ORCID ID

<https://orcid.org/0000-0001-5889-4391>

### Contact details

Vascular and Endovascular Research Network (President)  
Birmingham  
United Kingdom  
B15 2QU  
+44 (0)121 4143344  
vern.arterial.disease@gmail.com

### Type(s)

Scientific

### Contact name

Prof Christopher Imray

### Contact details

University Hospitals Warwickshire  
Department of Vascular Surgery  
Coventry  
United Kingdom  
CV22DX  
+44 (0)247 6964000  
vern.arterial.disease@gmail.com

### Type(s)

Scientific

### Contact name

Mr Athanasios Saratzis

**ORCID ID**

<https://orcid.org/0000-0002-3399-094X>

**Contact details**

BHF Cardiovascular Research Facility  
Glenfield Hospital  
Leicester  
United Kingdom  
LE39QP  
+44 (0)121 2524178  
vern.arterial.disease@gmail.com

**Type(s)**

Public

**Contact name**

Mr Sandip Nandhra

**Contact details**

Vascular and Endovascular Research Network  
Newcastle  
United Kingdom  
NE7 7DN  
+44 (0)191 2336161  
vern.arterial.disease@gmail.com

**Type(s)**

Scientific

**Contact name**

Prof Matt Bown

**ORCID ID**

<https://orcid.org/0000-0002-6180-3611>

**Contact details**

Department of Cardiovascular Sciences  
University of Leicester  
BHF Cardiovascular Research Centre  
Glenfield General Hospital  
Leicester  
United Kingdom  
LE2 7LX  
+44 (0)116 252 3190  
mjb42@le.ac.uk

**Type(s)**

Public

**Contact name**

Ms Ann Elsworth

**Contact details**

Office 65  
Clinical Sciences Building  
Glenfield Hospital  
Leicester  
United Kingdom  
LE3 9QP  
+44 (0)116 2502381  
ame29@le.ac.uk

**Additional identifiers****Clinical Trials Information System (CTIS)**

Nil known

**Integrated Research Application System (IRAS)**

282224

**Protocol serial number**

COVER\_01, IRAS 282224

**Study information****Scientific Title**

The impact of the COVID-19 pandemic on the provision, practice, and outcomes of vascular surgery. An international cohort study (COVER)

**Acronym**

COVER

**Study objectives**

The COVID-19 pandemic has already had a significant impact on worldwide healthcare systems. There is an urgent need to quantify the specific impact on the provision of vascular and endovascular surgery and the adjustments made to standard vascular practice in light of the pandemic.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Approved 02/04/2020, Liverpool Central NHS Research Ethics Committee (Barlow House, 3rd Floor, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 (0)207 104 8056; liverpoolcentral.rec@hpa.nhs.uk), ref: 20/NW/0196

**Study design**

Observational longitudinal study

## Primary study design

Observational

## Study type(s)

Other

## Health condition(s) or problem(s) studied

Any vascular condition, including: aortic or other type of aneurysmal disease, peripheral arterial disease, venous disease, vascular malformations, trauma, major haemorrhage, access (for renal dialysis), carotid (and cerebrovascular) disease, any other type of pathology treated by vascular surgeons.

## Interventions

This project is a three-tiered study designed to fully elucidate the impact of the COVID-19 pandemic on vascular surgery across the world.

The aim of Tier 1 is to document how the provision and availability of vascular services evolves over time per unit/region/country.

The aim of Tier 2 is to prospectively capture data on all vascular procedures performed during the pandemic and understand the impact on outcomes in the short and medium-term (up to 1 year).

The aim of Tier 3 is to document (prospectively) deviations from standards of care/practice during the pandemic in vascular patients.

The main objective of the COVER study is to understand and evaluate the impact of the COVID-19 pandemic on global vascular practice and the effect on outcomes for patients presenting/receiving treatment during the pandemic.

Population (patients) – All patients with a vascular pathology.

Outcome of interest – Tier 1: state of vascular services per centre weekly; Tier 2: procedures performed in each centre; Tier 3: assessment of longer-term outcomes.

Time – end of study 12 months after the end of the COVID19 pandemic.

The study is formally supported by the Vascular Society of Great Britain and Ireland (VSGBI), the British Society for Endovascular Therapy (BSET), the Rouleaux Club, the NIHR, SingVasc and several national vascular surgery societies in Europe, Asia, Australia, New Zealand, and the Americas.

## Intervention Type

Other

## Primary outcome(s)

1. Structure and processes within the vascular service measured using a novel online questionnaire weekly until the end of data collection
2. Document all vascular surgery and interventional procedures performed using an online purpose-built data collection tool (per centre/patient) at baseline, time/date of surgery, date of discharge from hospital, three, six, and twelve months:
  - 2.1. Type of procedure performed
  - 2.2. Time taken from presentation to the surgical team to intervention
  - 2.3. Mode of referral (primary vs. secondary care)

- 2.4. Site of surgery – hub or spoke hospital
- 2.5. Imaging modalities used and timings
- 2.6. Emergency classification i.e. urgent/emergency/elective
- 2.7. Operative technique(s) and device(s) used
- 2.8. Mode(s) of anaesthesia (local, regional, general, locoregional, other)
- 2.9. Whether suspected or confirmed COVID-19 positive (+ve) at time of surgery, COVID-19 +ve after surgery, or COVID-19 negative (-ve)
- 2.10. Documentation of changes to usual practice for this specific procedure as per surgeon's standard protocol (type of procedure, type of anaesthetic, post-procedural destination)
- 3. Management of all referred urgent vascular cases using the online survey, focusing on:
  - 3.1. Chronic Limb Threatening Ischaemia (CLTI):
    - 3.1.1. Decision to discharge/admit/refer to a "hot"/emergency clinic
    - 3.1.2. Decision for endovascular or open surgery first
    - 3.1.3. Decision for best medical therapy or palliation or primary amputation
  - 3.2. Carotid disease:
    - 3.2.1. Number of patients managed with best medical therapy (BMT)
    - 3.2.2. Modifications to the indication and decision for carotid endarterectomy (CEA)
    - 3.2.3. Delays to treatment due to lack of theatre/bed availability
  - 3.3. Abdominal Aortic Aneurysm (AAA)
    - 3.3.1. Increasing use of Endovascular repair (if applicable)
    - 3.3.2. Changes to criteria for intervention
    - 3.3.3. Decisions for palliation, i.e. 'turn down'
  - 3.4. Acute Aortic syndrome (AAS)
    - 3.4.1. Decision to manage in non-critical care beds
    - 3.4.2. Changes to imaging protocol at unit level
    - 3.4.3. Decision to defer surgery

### **Key secondary outcome(s)**

- 1. Collected after surgery has been performed at three, six, and twelve months using patient records:
  - 1.1. Re-admission
  - 1.2. Re-intervention
  - 1.3. All-cause mortality
  - 1.4. Operation-specific morbidity
  - 1.5. Morbidity
  - 1.6. [If COVID-19 +ve] - respiratory outcome, admission to intensive care unit
- 2. Condition-specific outcomes at 3, 6 months and 1 year:
  - 2.1. CLTI - limb salvage, amputation free survival, all-cause mortality
  - 2.2. Carotid disease - ipsilateral stroke rate, any stroke rate, all-cause mortality
  - 2.3. AAA - aneurysm-related mortality, all-cause mortality
  - 2.4. AAS - complication rate including ruptures, all-cause mortality

### **Completion date**

01/04/2022

## **Eligibility**

### **Key inclusion criteria**

Any patient with a vascular condition

### **Participant type(s)**

All

**Healthy volunteers allowed**

No

**Age group**

All

**Sex**

All

**Key exclusion criteria**

Does not meet inclusion criteria

**Date of first enrolment**

09/04/2020

**Date of final enrolment**

01/04/2022

**Locations**

**Countries of recruitment**

United Kingdom

England

Afghanistan

Albania

Algeria

American Samoa

Andorra

Angola

Anguilla

Antarctica

Antigua and Barbuda

Argentina

Armenia

Aruba

Australia  
Austria  
Azerbaijan  
Bahamas  
Bahrain  
Bangladesh  
Barbados  
Belarus  
Belgium  
Belize  
Benin  
Bermuda  
Bhutan  
Bolivia  
Bonaire Saint Eustatius and Saba  
Bosnia and Herzegovina  
Botswana  
Bouvet Island  
Brazil  
British Indian Ocean Territory  
Brunei Darussalam  
Bulgaria  
Burkina Faso  
Burundi  
Cabo Verde  
Cambodia

Cameroon

Canada

Cayman Islands

Central African Republic

Chad

Chile

China

Christmas Island

Cocos (Keeling) Islands

Colombia

Comoros

Congo

Congo, Democratic Republic

Cook Islands

Costa Rica

Croatia

Cuba

Curaçao

Cyprus

Czech Republic

Côte d'Ivoire

Denmark

Djibouti

Dominica

Dominican Republic

Ecuador

Egypt  
El Salvador  
Equatorial Guinea  
Eritrea  
Estonia  
Eswatini  
Ethiopia  
Falkland Islands  
Faroe Islands  
Fiji  
Finland  
France  
French Guiana  
French Polynesia  
French Southern Territories  
Gabon  
Gambia  
Georgia  
Germany  
Ghana  
Gibraltar  
Greece  
Greenland  
Grenada  
Guadeloupe  
Guam

Guatemala

Guernsey

Guinea

Guinea-Bissau

Guyana

Haiti

Heard Island and McDonald Islands

Holy See (Vatican City State)

Honduras

Hong Kong

Hungary

Iceland

India

Indonesia

Iran

Iraq

Ireland

Isle of Man

Israel

Italy

Jamaica

Japan

Jersey

Jordan

Kazakhstan

Kenya

Kiribati

Korea, North

Korea, South

Kosovo

Kuwait

Kyrgyzstan

Lao People's Democratic Republic

Latvia

Lebanon

Lesotho

Liberia

Libya

Liechtenstein

Lithuania

Luxembourg

Macao

Madagascar

Malawi

Malaysia

Maldives

Mali

Malta

Marshall Islands

Martinique

Mauritania

Mauritius

Mayotte

Mexico

Micronesia, Federated States of

Moldova

Monaco

Mongolia

Montenegro

Montserrat

Morocco

Mozambique

Myanmar

Namibia

Nauru

Nepal

Netherlands

New Caledonia

New Zealand

Nicaragua

Niger

Nigeria

Niue

Norfolk Island

North Macedonia

Northern Mariana Islands

Norway

Oman

Pakistan

Palau

Palestine, State of

Panama

Papua New Guinea

Paraguay

Peru

Philippines

Pitcairn

Poland

Portugal

Puerto Rico

Qatar

Romania

Russian Federation

Rwanda

Réunion

Saint Barthélemy

Saint Helena, Ascension and Tristan da Cunha

Saint Kitts and Nevis

Saint Lucia

Saint Martin (French part)

Saint Pierre and Miquelon

Saint Vincent and the Grenadines

Samoa

San Marino

Sao Tome and Principe

Saudi Arabia

Senegal

Serbia

Seychelles

Sierra Leone

Singapore

Sint Maarten (Dutch part)

Slovakia

Slovenia

Solomon Islands

Somalia

South Africa

South Georgia and the South Sandwich Islands

South Sudan

Spain

Sri Lanka

Sudan

Suriname

Svalbard and Jan Mayen

Sweden

Switzerland

Syria

Taiwan

Tajikistan

Tanzania

Thailand  
Timor-Leste  
Togo  
Tokelau  
Tonga  
Trinidad and Tobago  
Tunisia  
Turkmenistan  
Turks and Caicos Islands  
Tuvalu  
Türkiye  
Uganda  
Ukraine  
United Arab Emirates  
United States Minor Outlying Islands  
United States of America  
Uruguay  
Uzbekistan  
Vanuatu  
Venezuela  
Viet Nam  
Virgin Islands, British  
Virgin Islands, U.S.  
Wallis and Futuna  
Western Sahara  
Yemen

Zambia

Zimbabwe

**Study participating centre**

**University Hospital Coventry and Warwickshire (lead Research and Development centre)**

University Hospital Coventry and Warwickshire, RD&I (FAO Professor Imray)

Coventry

United Kingdom

CV2 2DX

## Sponsor information

**Organisation**

University Hospitals Coventry and Warwickshire NHS Trust

**ROR**

<https://ror.org/025n38288>

## Funder(s)

**Funder type**

Government

**Funder Name**

National Institute for Health Research

**Alternative Name(s)**

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

# Results and Publications

## Individual participant data (IPD) sharing plan

Not provided at registration

## IPD sharing plan summary

Available on request

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		01/04/2021	06/12/2021	Yes	No
<a href="#">Results article</a>		01/10/2020	06/12/2021	Yes	No
<a href="#">Results article</a>	Qualitative results of clinician survey	03/12/2021	06/12/2021	Yes	No
<a href="#">Protocol article</a>		30/12/2020	06/12/2021	Yes	No
<a href="#">Abstract results</a>	Presented at National Research Collaborative Meeting Conference 2020	08/04/2021	06/12/2021	No	No
<a href="#">HRA research summary</a>			28/06/2023	No	No
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes